Abstract Background The National Institutes of Health Office of Medical Applications of
Research commissioned a structured literature review on the incidence, treatment, and …

Ductal carcinoma in situ of the breast (also called intraductal carcinoma), a clonal
proliferation of malignant-appearing cells within the mammary duct lumens without evidence …

Background: Twenty-one states have laws requiring that women be notified if they have
dense breasts and that they be advised to discuss supplemental imaging with their provider …

Background: Despite trials of mammography and widespread use, optimal screening policy
is controversial. Objective: To evaluate US breast cancer screening strategies. Design: 6 …

Research methods for biomarker evaluation lag behind those for evaluating therapeutic
treatments. Although a phased approach to development of biomarkers exists and …

Validated biomarkers are needed to improve risk assessment and treatment decision-
making for women with ductal carcinoma in situ (DCIS) of the breast. The Onco type DX® …

Background: Current guidelines recommend mammography every 1 or 2 years starting at
age 40 or 50 years, regardless of individual risk for breast cancer. Objective: To estimate the …

Background Studies have failed to identify characteristics of women who have been
diagnosed with ductal carcinoma in situ (DCIS) and have a high or low risk of subsequent …

Oncoplastic surgery refers to several surgical techniques by which segments of malignant
breast tissue are removed to achieve wide surgical margins while the remaining glandular …

Ductal carcinoma in situ (DCIS) is a relatively common diagnosis among women undergoing
screening mammography. The greatest increases in DCIS incidence have been in non …